Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib and Caelyx in HER2+ Metastatic Breast Cancer
NCT00903656Phase 2Terminated
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- May 2009
- Primary completion
- May 2012
- Countries
- 1
01
Overview
Phase 2, open-label trial of lapatinib in breast cancer, sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Primary endpoint: Overall Response Rate. Started May 2009; status: terminated.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00903656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00903656.